17Jan/14

2014 Outlook: New Drugs in Hepatitis C, MS, Oncology Are Expected This Year – Atlantic Information Services, Inc.

2014 Outlook: New Drugs in Hepatitis C, MS, Oncology Are Expected This Year
Atlantic Information Services, Inc.
to approve it (see story, p. 1). Other potential additions, she says, include Teva’s laquinimod, Biogen Idec and Abbott Laboratories’ daclizumab and ocrelizumab from Biogen Idec and Roche. © 2014 by Atlantic Information Services, Inc. All Rights

17Jan/14

Biogen Idec-Aktie: Prall gefüllte Pipeline – Kaufen – Nomura Securties … – AktienCheck

Biogen Idec-Aktie: Prall gefüllte Pipeline – Kaufen – Nomura Securties
AktienCheck
Der Fokus von Aktienanalyst M. Ian Somaiya liege für das Börsenjahr 2014 auf den Phase-III MS Daten der USD 2 Mrd.-Chance daclizumab zur Jahresmitte und den anti-LINGO-Phase-II-Daten im vierten Quartal 2014. Aktienanalyst M. Ian Somaiya